Related Experiment Video
Updated: Jan 11, 2026

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
Synergistic Therapeutic Efficacy of Engineered Probiotics Embedded in Self-Assembling Keratin Hydrogels for
Yijiao Wen1, Chunhua Zhang1, Xuanting Wang1
1Green Pharmaceutical Technology Key Laboratory of Luzhou, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Abstract:
Efficient oral delivery and sustained viability of probiotics remain significant obstacles to the clinical translation of live biotherapeutics. Therefore, in this study, we developed self-assembling keratin hydrogels derived from feather waste using a disulfide shuffling strategy for probiotic encapsulation. This cost-effective and scalable approach substantially improved the gastrointestinal tolerance and oral bioavailability of multiple probiotics, including Escherichia coli Nissle 1917 (EcN), Bacillus licheniformis, Lactococcus lactis, and Bifidobacterium bifidum. To achieve site-specific release in the intestinal tract, EcN was engineered to express keratinase (EcNker), enabling hydrogel degradation in the gut. In dextran sulfate sodium-induced colitis model mice, hydrogel-encapsulated EcNker exhibited markedly superior therapeutic efficacy over unencapsulated probiotics, as indicated by the amelioration of clinical symptoms, restoration of colon histology, attenuation of intestinal apoptosis, and normalization of inflammatory cytokine profiles. Mechanistically, hydrogel-encapsulated EcNker treatment restored the gut barrier integrity by upregulating the tight junction protein levels, modulating gut microbiota by increasing the number of beneficial genera, and enhancing short-chain fatty acid production. Collectively, our findings highlight the potential of keratin hydrogels as universal biocompatible and efficient delivery platforms for orally engineered probiotics to treat colonic colitis and other diseases.
More Related Videos
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

